Pharma industry venture financing deals in March 2019 total $1.17bn globally

26 April 2019 (Last Updated April 26th, 2019 06:25)

Pharma industry venture financing deals in March 2019 total $1.17bn globally

Total pharma industry venture financing deals in March 2019 worth $1.17bn were announced globally, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

The value marked a decrease of 34.8% over the previous month and a drop of 35.6% when compared with the last 12-month average, which stood at $1.81bn.

Comparing deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $833.44m. At the country level, the US topped the list in terms of deal value at $833.44m.

In terms of volumes, North America emerged as the top region for pharma industry venture financing deals globally, followed by Asia-Pacific and then Europe.

The top country in terms of venture financing deals activity in March 2019 was the US with 61 deals, followed by China with nine and Switzerland with three.

In 2019, as of the end of March 2019, pharma venture financing deals worth $4.93bn were announced globally, marking a decrease of 13.8% year on year.

Pharma industry venture financing deals in March 2019: Top deals

The top five pharma industry venture financing deals accounted for 33.1% of the overall value during March 2019.

The combined value of the top five pharma industry venture financing deals stood at $386m, against the overall value of $1.17bn recorded for the month. The top announced pharma industry venture financing deal tracked by GlobalData in March 2019 was Altitude Life Science Ventures, ARCH Venture Partners, Cormorant Asset Management, Eight Roads Ventures, F-Prime, Omega Fund Management and Redmile Group’s $135m venture financing of Beam Therapeutics.

In second place was the $70m venture financing of InventisBio by Advantech Capital, CMB International Capital, Lilly Asia ventures, OrbiMed Asia Partners and Pudong Innotek Capital and in third place was Alexandria Venture Investments, ARCH Venture Partners, Eventide Asset Management, Fidelity Management & Research, Partner Fund Management, Pivotal bioVenture Partners, Puretech Health, Sands Capital Management and Wellcome Trust’s $68m venture financing of Karuna Therapeutics.

The $63m venture financing of Imara by Alexandria Venture Investments, Arix Bioscience, Bay City Capital, Lundbeckfond Ventures, New Enterprise Associates, Orbimed Advisors, Pfizer Venture Investments, RA Capital Management and Rock Springs Capital Management and AbbVie Ventures, Adage Capital Management, Alexandria Venture Investments, Boxer Capital, BVF Partners, EcoR1 Capital, Omega Fund Management, Orbimed Advisors, Pontifax, RA Capital Management and Surveyor Capital’s venture financing of Prevail Therapeutics for $50m held fourth and fifth positions, respectively.

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.